MedTrace Logo

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

NCT04008797 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 301

Last updated 2026-03-24

No results posted yet for this study

Summary

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).

Conditions

  • Endometrial Neoplasms
  • Neoplasms
  • Carcinoma, Hepatocellular
  • Liver Neoplasms
  • Colorectal Neoplasms

Interventions

DRUG

E7386

E7386 dosing.

DRUG

Lenvatinib

Lenvatinib dosing.

DRUG

Doxorubicin

Doxorubicin dosing.

DRUG

Paclitaxel

Paclitaxel dosing.

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-11
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • China
  • Denmark
  • France
  • Italy
  • Japan
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04008797 on ClinicalTrials.gov